SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

<div>Waterfall plots showing change in 2-dimensional tumor measurements according to WHO criteria after 4 cycles (2 cycles ifosfamide and doxorubicin, IA, and 2 cycles of ifosfamide and etoposide, IE, upper panels) and 2 cycles (IA, lower panels). On all four panels patients are arranged by best response measured after cycle 4. <sup>★</sup>Patients removed from treatment after cycle 2. <sup>❖</sup>Target lesion stable, but progressive disease with new lesion.</div>

Sarcoma

fig2

Figure 2

Figure 2: SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors 

Figure 2 | SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors 